Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Propella Therapeutics
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Propella Therapeutics developed a proprietary lymphatic targeting platform to enhance delivery of small molecule drugs for oncology and pain. Its lead candidate, PRL‑02, an androgen biosynthesis inhibitor for prostate cancer, reached the clinical stage before the company was acquired by Astellas Pharma in December 2023. Other pipeline assets include a TRPV1 agonist for pain and a preclinical herpes simplex therapy.
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Acquired by Astellas Pharma Inc.; no other major partnerships disclosed publicly at time of acquisition.
Beyond the preview
Go deeper on Propella Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Propella Therapeutics.